Autologous stem cell transplant (ASCT) for AIDS- related lymphoma (ARL). Proocedings of the 11th International Conference on Malignancies and other Immunodeficiencies (ICMAOI): Basic, Epidemiological and Clinical Reserch. Bethesda, MD, 6-7 October, 2008; abs O41, pag.20...
STEM cell transplantationLYMPHOMA treatmentDISEASE progressionThis article discusses a retrospective study conducted in China on the use of autologous stem cell transplant (ASCT) for refractory and relapsed peripheral T-cell lymphoma (PTCL). The study found that ASCT can improve outcomes for R...
Patients with multiple myeloma receiving ASCT showed a 10% increase in tumor cell reduction. Recent findings from a phase 3 clinical trial suggest that patients with multiple myeloma who received an autologous stem cell transplant (ASCT) had longer progression-free survival compared with patients ...
Autologous hematopoietic stem-cell transplantation (auto-HSCT) is a transplant technique in which stem cells are removed from the patient (apheresis), stored, and later given back to that same patient. Before auto-HSCT, the patient is subjected to intensive treatment with high-dos...
Autologous Peripheral Stem-Cell Transplantation autologous protein Autologous Serum Eye Drops autologous serum skin test Autologous Skeletal Muscle Grafts autologous sling procedure autologous stem cell rescue Autologous Stem Cell Transplant autologous stem cell transplantation ...
Bone Marrow TransplantBone Marrow TransplantationPerentesis J,Katsanis E,DeFor T,Neglia J,Ramsay N.Autologous stem cell transplantation for high-risk pediatric solid tumors.Bone Marrow Transplantation. 1999Perentesis J, Katsanis E, DeFor T, et al: Autologous stem-cell transplantation for high-risk ...
ASCT is feasible in selected elderly patients with multiple myeloma and those with non-Hodgkin's lymphoma. As elderly patients have generally been excluded from randomized studies evaluating efficacy of ASCT in comparison with non-transplant approaches, limited data are available on the efficacy of ...
(HealthDay)—Autologous stem cell transplantation (ASCT) may be beneficial for some patients with nodal peripheral T-cell lymphoma (PTCL) in the first complete remission (CR1), according to a study published online Jan. 29 in Cancer.
The use of autologous stem cell transplantation (ASCT) as consolidation therapy for adult patients with acute leukemia has declined over time. However, multiple randomized studies in the past have reported lower relapse rates after autologous transplanta
One patient died within 100 days of transplant representing a 2% 100-day mortality rate. ASCT is safe and efficacious in carefully selected MM patients aged 75 or above and we believe that age should not be an exclusion factor for ASCT in MM. This is a preview of subscription content, ...